Trientine for treatment of Wilson's disease: clinical and cost-effectiveness, and safety

Record ID 32014000821
Authors' recommendations: One relevant systematic review and three non-randomized studies were identified regarding the clinical effectiveness and safety of trientine for the treatment of Wilsons disease. No information on cost-effectiveness was identified.
Project Status: Completed
Year Published: 2014
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Hepatolenticular Degeneration
  • Cost-Benefit Analysis
  • Safety
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.